EUVIMEDEUVIMED entdecken
Editorial

Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?

Shuntaro Obi, Masao Omata

Hepatology International · 2026-06 · 20 (3) · 556-558

DOI: 10.1007/s12072-026-11089-1 ↗

Kurz gefasst

Editorial in der Zeitschrift Hepatology International, online erschienen am 19.04.2026. Verfasst von Shuntaro Obi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. obis@med.teikyo-u.ac.jp. Die Arbeit nennt 11 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Internal Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara, Chiba, 299-0111, Japan. obis@med.teikyo-u.ac.jp.
  • Department of Gastroenterology, Yamanashi Prefectural Central Hospital, Yamanashi, Japan.
  • The University of Tokyo, Tokyo, Japan.

Zitieren

APA

Obi, S., & Omata, M. (2026). Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?. Hepatology International, 20(3), 556-558. https://doi.org/10.1007/s12072-026-11089-1

Vancouver

Obi S, Omata M. Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?. Hepatology International. 2026;20(3):556-558. doi:10.1007/s12072-026-11089-1

BibTeX
@article{Obi2026,
  author = {Obi, Shuntaro and Omata, Masao},
  title = {Is triple therapy redefining first-line treatment in intermediate-advanced hepatocellular carcinoma?},
  journal = {Hepatology International},
  year = {2026},
  volume = {20},
  number = {3},
  pages = {556--558},
  doi = {10.1007/s12072-026-11089-1}
}
Kostenlos starten →